Open AccessEfficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness—A Double-blind, Randomized, Placebo-controlled Phase 3 Study
Author(s) -
Hinrich Staecker,
Galina Jokovic,
S. А. Karpishchenko,
Andrea Kienle-Gogolok,
Andrzej Krzyzaniak,
ChiaDer Lin,
Pavel Navrátil,
Ventzislav Tzvetkov,
Nida Wright,
Thomas Meyer
Publication year - 2019
Publication title -
otology and neurotology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.147
H-Index - 104
eISSN - 1537-4505
pISSN - 1531-7129
DOI - 10.1097/mao.0000000000002229
Subject(s) - medicine , clinical endpoint , placebo , tinnitus , hearing loss , adverse effect , population , audiology , randomized controlled trial , anesthesia , alternative medicine , environmental health , pathology
To confirm the efficacy and safety of AM-111 (brimapitide), a cell-penetrating c-Jun N-terminal Kinase (JNK) inhibitor, in patients suffering from severe to profound acute unilateral idiopathic sudden sensorineural hearing loss (ISSNHL).